Making decisions about hormone replacement therapy: Bisphosphonates should not be recommended for women aged 50

BMJ

Volumn 326, Issue 7403, 2003, Pages 1398-

  Ott, Susan M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007664475     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.326.7403.1398-a     Document Type: Letter

References (5)

1. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ 2003; 326: 322–6. (8 February.)
2. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med 1999; 131: 935–42.
3. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333–40.
4. Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B. Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 2001; 86: 5700–5.
5. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997; 100: 1475–80.